Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BCL2 | P10415 | 6/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656153 | 0.86 | MMP2 (0.43) | ALDH1A1TSHRBCL2MCL1CA1 | |
| SCHEMBL6565711 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRFOLH1PPARGPPARA | |
| SCHEMBL6564143 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TSHRBCL2MCL1PPARG | |
| SCHEMBL6564213 | 0.84 | CXCR1 (0.42) | ALDH1A1BCL2MCL1CA1CA2 | |
| SCHEMBL6563381 | 0.81 | MAPK1 (0.43) | ALDH1A1BCL2MCL1CA1CA2 | |
| SCHEMBL6563000 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TSHRFOLH1SIRT5CTSK | |
| SCHEMBL6563192 | 0.79 | CXCR2 (0.51) | ALDH1A1TSHRSIRT5 | |
| SCHEMBL6564159 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRFOLH1CA1CA2 | |
| SCHEMBL7498490 | 0.77 | ALDH1A1 (0.49) | ALDH1A1TSHRFOLH1TGM2CA1 | |
| SCHEMBL3726205 | 0.76 | ALDH1A1 (0.89) | ALDH1A1TSHRFOLH1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| CN-1334726-A | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2002-02-06 | — | — | CN | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | ALDH1A1 1321/4885TSHR 1480/4885BCL2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.